Market revenue in 2023 | USD 3,037.1 million |
Market revenue in 2030 | USD 6,958.9 million |
Growth rate | 12.6% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.84% in 2023. Horizon Databook has segmented the U.S. immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
Local presence of key market players in the country is anticipated to increase the penetration of novel biomarkers. Major players operating in the market include Abbott, Merck & Co., Inc., Johnson & Johnson Services, Inc., Thermo Fisher Scientific, Inc., and Bio-Rad Laboratories, Inc.
Furthermore, many academic institutions, research centers, and universities are collaborating with key market players to develop biomarkers for diagnosing and monitoring various diseases. Increasing efforts for the development of digital biomarkers and rising investments & collaboration activities are anticipated to drive market growth.
Moreover, key players are focusing on new immunoassay products that can increase the commercialization of novel immunoassays for the identification of neurological biomarkers. For instance, in December 2022, the U.S.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into U.S. immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account